5.96
Verrica Pharmaceuticals Inc Aktie (VRCA) Neueste Nachrichten
Sentiment analysis tools applied to Verrica Pharmaceuticals Inc.Wall Street Watch & Long-Term Investment Growth Plans - Newser
Real time social sentiment graph for Verrica Pharmaceuticals Inc.2025 EndofYear Setup & Intraday High Probability Alerts - Newser
Sector ETF Data Correlates with Strength in Verrica Pharmaceuticals Inc.Trade Analysis Report & Growth Oriented Trading Recommendations - sundaytimes.kr
What makes Verrica Pharmaceuticals Inc. stock price move sharply2025 Earnings Surprises & Stock Portfolio Risk Control - Newser
Market reaction to Verrica Pharmaceuticals Inc.’s recent newsOptions Play & Weekly Breakout Watchlists - Newser
Historical volatility pattern of Verrica Pharmaceuticals Inc. visualized2025 Major Catalysts & Long Hold Capital Preservation Plans - Newser
Can Verrica Pharmaceuticals Inc. recover in the next quarterEarnings Growth Summary & Stock Portfolio Risk Control - Newser
Verrica Pharmaceuticals Inc. Company’s Quarterly Earnings Growth: What the Numbers SayMarket Volume Report & Risk Adjusted Swing Trade Ideas - Newser
Verrica Pharmaceuticals shares rise 2.28% after-hours following Q2 2025 earnings call. - AInvest
Verrica Pharmaceuticals stock price target raised to $20 by TD Cowen - Investing.com Canada
Verrica Pharmaceuticals Reaches Nasdaq Compliance, Q2 Revenue at $12.7M - AInvest
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Q2 2025 Earnings Call Transcript - Insider Monkey
Verrica Pharmaceuticals Inc. (VRCA) Q2 Earnings and Revenues Beat Estimates - MSN
Why Verrica Pharmaceuticals Inc. stock attracts strong analyst attentionJobs Report & High Win Rate Trade Alerts - Newser
Verrica Pharmaceuticals Inc (VRCA) Q2 2025 Earnings Call Highlights: Record Revenue Growth and ... - Yahoo Finance
Verrica Pharmaceuticals Inc (VRCA) Q2 2025 Earnings Call Highlig - GuruFocus
Verrica Pharmaceuticals Sees Revenue Surge in Q2 2025 - TipRanks
Verrica Pharmaceuticals Reports Second Quarter 2025 Financial Results - GlobeNewswire
Verrica Posts Profit in Fiscal Q2 - The Motley Fool
Verrica Posts Profit in Fiscal Q2 - Nasdaq
Verrica Pharmaceuticals' Q2 2025: Unpacking Contradictions in Sales Strategies, Seasonality, and Patient Access - AInvest
Verrica Pharmaceuticals (VRCA) Q2 2025 Earnings and Strategic Pipeline Catalysts: A Case for Re-Rating and Investor Re-Entry - AInvest
Earnings call transcript: Verrica Pharmaceuticals Q2 2025 beats EPS forecast By Investing.com - Investing.com Nigeria
VERRICA PHARMACEUTICAL Earnings Results: $VRCA Reports Quarterly Earnings - Quiver Quantitative
Verrica Pharmaceuticals earnings beat by $0.11, revenue topped estimates - Investing.com Canada
Verrica Pharmaceuticals Inc. stock trend outlook and recovery pathFree Short Term Trading Opportunity Watch - Newser
Verrica Pharmaceuticals Inc (VRCA) Q2 2025: Everything You Need To Know Ahead Of Earnings - Yahoo Finance
Verrica VRCA 2025Q2 Earnings Preview Upside Potential on Strategic Expansion Plans - AInvest
Verrica Pharmaceuticals to Report Q2 Results on August 12 - MSN
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Receives $80.00 Average PT from Analysts - Defense World
Is Verrica Pharmaceuticals Inc. showing signs of accumulationEarnings Impact and Stock Reaction Analysis - Newser
Verrica Pharmaceuticals to Report Second Quarter 2025 Financial - GuruFocus
Verrica Pharmaceuticals to Report Q2 2025 Financial Results and Provide Corporate Update on Aug 12, 2025. - AInvest
Verrica Pharmaceuticals to host Q2 earnings call on August 12, 2025. - AInvest
Verrica Pharmaceuticals: A Strategic Leap from Niche to Diversified Biotech Leader - AInvest
Verrica Pharmaceuticals to report second quarter 2025 financial results and provide a corporate update on August 12, 2025 - MarketScreener
Verrica Pharmaceuticals (VRCA): A Turning Point in 2025 Q2 Earnings and Strategic Momentum - AInvest
Verrica Pharmaceuticals to Report Second Quarter 2025 - GlobeNewswire
Verrica Pharmaceuticals Sets Q2 Earnings Date: Key Updates Expected on Dermatology Pipeline - Stock Titan
Common Warts Clinical Trials, Companies, Therapeutic - openPR.com
Common Warts Clinical Trials, Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, Pipeline Analysis | Verrica Pharmaceuticals, X4 Pharmaceuticals, Phio Pharmaceuticals, Kino Ph - Barchart.com
Verrica Pharmaceuticals Inc. Consolidation Zone May Signal AccumulationTrade Setups With Clear Risk Limits Highlighted - metal.it
Published on: 2025-08-04 09:22:19 - metal.it
What drives Verrica Pharmaceuticals Inc. stock priceAchieve rapid capital gains with smart investing - Jammu Links News
What analysts say about Verrica Pharmaceuticals Inc. stockAchieve consistent profits with disciplined trading - Jammu Links News
How volatile is Verrica Pharmaceuticals Inc. stock compared to the marketUnmatched profit potential - Jammu Links News
Is it the right time to buy Verrica Pharmaceuticals Inc. stockMaximize gains with proven stock analysis - Jammu Links News
Should I hold or sell Verrica Pharmaceuticals Inc. stock in 2025Unlock market-leading stock analysis - Jammu Links News
Why is Verrica Pharmaceuticals Inc. stock attracting strong analyst attentionOutstanding capital appreciation - Jammu Links News
What is the dividend policy of Verrica Pharmaceuticals Inc. stockOutperformance with explosive growth - Jammu Links News
What are the technical indicators suggesting about Verrica Pharmaceuticals Inc.Free Investment Community - Jammu Links News
How does Verrica Pharmaceuticals Inc. compare to its industry peersCapitalize on fast-moving trading opportunities - Jammu Links News
How many analysts rate Verrica Pharmaceuticals Inc. as a “Buy”Beginner Investor Insights That Work - jammulinksnews.com
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):